Results 81 to 90 of about 231,796 (189)

Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors [PDF]

, 2018
Background. Neuroendocrine tumors (NETs) are characterized by having behavior and prognosis that depend upon tumor histology, primary site, staging, and proliferative index.
Baldelli, Roberto, Campana, Davide, Di Giacinto, Paola, Isidori, Andrea, Lania, Andrea, Lenzi, Andrea, Rizza, Laura, Rota, Francesca, Zuppi, Paolo   +8 more
core   +1 more source

Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer

Molecular Oncology, EarlyView.
This study employed targeted metabolomic profiling to identify 302 distinct metabolites present in platelet‐rich plasma (PRP), revealing aberrant metabolic profiles amongst individuals diagnosed with colorectal cancer (CRC). Compared to carcinoembryonic antigen (CEA) and cancer antigen 19‐9 (CA199), our metabolite panel showed improved sensitivity ...
Zuojian Hu, Fenglin Shen, Yang Liu, Ziqing Zhong, Yongling Chen, Zhiyuan Xia, Cuiju Mo, Hongxiu Yu   +7 more
wiley   +1 more source

FOXM1 coming of age: time for translation into clinical benefits? [PDF]

, 2012
A decade since the first evidence implicating the cell cycle transcription factor Forkhead Box M1 (FOXM1) in human tumorigenesis, a slew of subsequent studies revealed an oncogenic role of FOXM1 in the majority of human cancers including oral ...
Teh, M-T
core   +1 more source

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

Molecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia, Anouk C. de Jong, Lisanne F. van Dessel, Vanja de Weerd, Corine Beaufort, Jean Helmijr, José Alberto Nakauma‐González, Job van Riet, Paul Hamberg, Daniel Vis, Michiel S. van der Heijden, Nick Beije, Martijn P. Lolkema, Teoman Deger, Saskia M. Wilting, Ronald de Wit, Maurice P. H. M. Jansen, John W. M. Martens   +17 more
wiley   +1 more source

Breast-Lesion Characterization using Textural Features of Quantitative Ultrasound Parametric Maps [PDF]

, 2017
© 2017 The Author(s). This study evaluated, for the first time, the efficacy of quantitative ultrasound (QUS) spectral parametric maps in conjunction with texture-analysis techniques to differentiate non-invasively benign versus malignant breast lesions.
A Ahmed, A Heindl, A König, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, AV Alvarenga, B Sigel, D Sengupta, E Feleppa, EJ Feleppa, EJ Feleppa, EJ Feleppa, EJ Feleppa, EJ Feleppa, F Davnall, FL Lizzi, FL Lizzi, FLL Lizzi, H Tadayyon, H Tadayyon, H Tadayyon, H Tadayyon, J Mamou, JPB O’Connor, K Polyak, KA Wear, KA Wear, KC Balaji, L Sannachi, LX Yao, M Vaidya, MJ Gerdes, ML Oelze, ML Oelze, ML Oelze, ML Oelze, ML Oelze, N Duric, N Sannomiya, R Natrajan, RJ Lavarello, RL Siegel, RM Haralick, S Chicklore, S Tan, T Cover, T Noritomi, TJ Larkin, V Goh, Y Labyed, Y Labyed, Y-Y Liao   +55 more
core   +2 more sources

Integration of single‐cell and bulk RNA‐sequencing data reveals the prognostic potential of epithelial gene markers for prostate cancer

Molecular Oncology, EarlyView.
Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley   +1 more source

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma [PDF]

, 2015
Accurate assessment of neuroblastoma outcome prediction remains challenging. Therefore, this study aims at establishing novel prognostic tumor DNA methylation biomarkers.
, Berbegall, Ana P., Bienertova-Vasku, Julie, Bown, Nick, Cannoodt, Robrecht, Clément, Nathalie, Combaret, Valérie, De Preter, Katleen, De Wilde, Bram, Decock, Anneleen, Haber, Michelle, Hoyoux, Claire, Laureys, Geneviève, Murray, Jayne, Noguera, Rosa, Ongenaert, Maté, Pierron, Gaelle, Schleiermacher, Gudrun, Schulte, Johannes H., Speleman, Frank, Stallings, Ray L., Tweddle, Deborah A., Van Roy, Nadine, Vandesompele, Jo, Verniers, Kimberly   +24 more
core   +2 more sources

MET variants with activating N‐lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation

Molecular Oncology, EarlyView.
MET variants in the N‐lobe of the kinase domain, found in hereditary papillary renal cell carcinoma, require ligand stimulation to promote cell transformation, in contrast to other RTK variants. This suggests that HGF expression in the microenvironment is important for tumor growth in such patients. Their sensitivity to MET inhibitors opens the way for
Célia Guérin, Audrey Vinchent, Marie Fernandes, Isabelle Damour, Agathe Laratte, Rémi Tellier, Gabriella O. Estevam, Jean‐Pascal Meneboo, Céline Villenet, Clotilde Descarpentries, James S. Fraser, Martin Figeac, Alexis B. Cortot, Etienne Rouleau, David Tulasne   +14 more
wiley   +1 more source

Etoposide‐induced cancer cell death: roles of mitochondrial VDAC1 and calpain, and resistance mechanisms

Molecular Oncology, EarlyView.
The complex mode of action of the topoisomerase II inhibitor etoposide in triggering apoptosis involves several mechanisms: overexpression of the mitochondrial protein VDAC1, leading to its oligomerization and formation of a large channel that mediates the release of pro‐apoptotic protein; and overexpression of the apoptosis regulators p53, Bax, and ...
Aditya Karunanithi Nivedita, Varda Shoshan‐Barmatz   +1 more
wiley   +1 more source

Biomarkers in Pancreatic Neuroendocrine Tumors

Journal of the Pancreas, 2014
The aim of biomarkers is to identify patients most likely to benefit from a therapeutic strategy. Pancreatic neuroendocrine tumors are rare neoplasms that arise in the endocrine tissues of the pancreas. Pancreatic neuroendocrine tumors represent 3% of primary pancreatic neoplasms and their incidence has risen.
Konstantinos N. Syrigos, Muhammad Wasif Saif, Maria Serafeim Theochari   +2 more
openaire   +2 more sources